What is ATAI Life Sciences NV Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ATAI Life Sciences NV's interest expense for the
three
months ended in Mar. 2024 was $ -0.69 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.72 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ATAI Life Sciences NV's Operating Income for the
three
months ended in Mar. 2024 was $ -23.88 Mil. ATAI Life Sciences NV's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.69 Mil.
ATAI Life Sciences NV did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ATAI Life Sciences NV Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ATAI Life Sciences NV's Interest Expense for the
three
months ended in Mar. 2024 was $-0.69 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-23.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $20.56 Mil.
ATAI Life Sciences NV's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| ATAI Life Sciences NV did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
| Florian Brand |
officer: See Remarks |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Anne Nagengast Johnson |
officer: Chief Accounting Officer |
C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
| Apeiron Investment Group Ltd. |
10 percent owner |
BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
| Sahil Kirpekar |
officer: Chief Business Officer |
C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
| Stephen Bardin |
officer: Chief Financial Officer |
C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117 |
| Gregory L Weaver |
officer: Chief Financial Officer |
185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
| Andrea Heslin Smiley |
director |
600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
| Michael Auerbach |
director |
158 HESTER STREET, APT 7F, NEW YORK NY 10013 |
| Amir H Kalali |
director |
4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121 |
| Christian Angermayer |
director, 10 percent owner |
BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
| Rosnay Alexis De |
director |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Srinivas Rao |
officer: See Remarks |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Sabrina Martucci Johnson |
director |
11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
| Jason Camm |
director |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Presight Ii, Lp |
10 percent owner |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
ATAI Life Sciences NV (ATAI Life Sciences NV) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 